DISCLAIMER This presentation of Loop Industries, Inc., a Nevada corporation ("Loop", the "Company," "we," or "our"), is dated March 13th , 2025, and contains "forward-looking information" and "forward-looking statements" within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and as defined in the U.S. Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). Such forward-looking statements include, but are not limited to, statements with ...

Strategy and Performance - Phillips 66's TSR outperformed its synthetic proxy peer median by 22% (67% vs 45%) since the 2022 CEO transition[18] - The company's integrated model results in a 39% higher return of capital to shareholders compared to its weighted proxy peer average over the last 10 years (646% vs 465%)[20, 21] - Phillips 66's average return on capital employed is 44% higher than its weighted proxy peer average over the last 10 years (107% vs 74%)[22, 23] - The company has a 15% compound annual growth rate (CAGR) in dividends[32, 36] - Phillips 66 has repurchased 35% of its initial shares outstanding since the 2012 spin-off[36] Refining - Phillips 66 aims to reduce refining costs to $550 per barrel by 2027[51] - The company reduced refining costs from $698 per barrel to $590 per barrel[50] - Every $050 per barrel of cost reduction is expected to improve adjusted EBITDA by approximately $315 million[66] Midstream - Phillips 66 projects Midstream adjusted EBITDA growth since 2021[78] - The company is projecting $975 million in Midstream capital spend in 2025[90] Chemicals - CPChem is expected to add approximately 7 million metric tons per annum (MMTA) of capacity through self-funded organic growth from 2017 to 2027[101, 143] - CPChem anticipates a 19% chain margin recovery by 2027[143] Synergies and Capital Allocation - Phillips 66 generates over $500 million in annual operating synergies through integration[106] - The company targets returning over 50% of net operating cash flow to shareholders[53, 114, 119]

AFM24 (EGFR) + atezolizumab in NSCLC - In EGFRwt NSCLC, the Disease Control Rate (DCR) was 76% (25/33 patients), with 48% (16/33) showing tumor shrinkage and an Objective Response Rate (ORR) of 21% (1 CR, 6 PRs)[16] - In EGFRmut NSCLC, the DCR was 71%, with 41% (7/17) showing tumor shrinkage and an ORR of 24% (1 CR, 3 PRs)[16] - Preliminary median Progression-Free Survival (PFS) in EGFRwt NSCLC was 5.6 months, with 36% of patients ongoing[33, 49] - Patients without prior taxane exposure in EGFRwt NSCLC showed a 25% ORR and a preliminary median PFS of 74 months[47, 53] - Post-hoc analysis showed increasing AFM24 exposure resulted in higher ORR, with the highest exposure group (Q4) achieving a 5455% ORR and a 9091% DCR[68] Acimtamig (AFM13) + AlloNK® in r/r HL - In relapsed/refractory Hodgkin Lymphoma (r/r HL), the ORR was 864% (19/22 patients), including a 545% Complete Response (CR) rate[16, 91] - All patients in the LuminICE-203 study were refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPIs)[80] AFM28 in r/r AML - In the highest dose level (300 mg), a composite complete remission rate (CRcR) of 40% (4/10 patients) was achieved in relapsed/refractory Acute Myeloid Leukemia (r/r AML)[16, 107]

Greatness Starts Here We transform organizations by building exceptional leaders, teams, and cultures that get results. © FranklinCovey Co. All rights reserved. PROPRIETARY AND CONFIDENTIAL INVESTOR UPDATE Third Quarter Fiscal 2025 Forward-Looking Statements/Non-GAAP This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon management's current expectations and are subject to various risks and u ...

Gedatolisib: A Novel PAM Inhibitor - Gedatolisib, a pan-PI3K/mTOR inhibitor, shows potential as a highly potent and cytotoxic agent with a differentiated mechanism of action and pharmacokinetic profile[7, 23] - Gedatolisib has demonstrated compelling preliminary results in HR+/HER2- advanced breast cancer (ABC) patients, with a median progression-free survival (mPFS) of 48 months in 1st line and 12.9 months in 2nd line settings[7, 23] - Gedatolisib is more potent against each node than other PAM inhibitors, with >300X higher potency and 1.5x – 2.8x higher cytotoxicity than other PAM inhibitors in vitro[30] - Gedatolisib has a lower rate of Grade 3/4 hyperglycemia (>95% lower) and treatment-related discontinuations (>80% lower) compared to approved PI3K inhibitors[31] Clinical Development and Market Opportunity - Celcuity is conducting a Phase 3 study in 2nd line HR+/HER2- ABC patients and expects to begin enrolling a Phase 3 study in 1st line patients in Q2 2025[7, 158] - The PAM pathway is the most frequently altered pathway in solid tumors (38%), yet drug revenues from PAM inhibitors are a small fraction of other targeted therapy classes[10, 18] - The potential patient population for PAM inhibitors in breast and prostate cancers is estimated to be >500,000 in the US, EU5, and Japan[10] - US market opportunity for Gedatolisib in HR+/HER2- Breast Cancer and Advanced Prostate Cancer is estimated at ~$5-$6 Billion for 2L ABC Post-CDKi + AI, ~$10B+ for 1L ABC ET Sensitive, ~$3B for 1L ABC ET Resistant, $6-$8B for High Risk EBC Adjuvant, $8B+ for 1L/2L mCRPC Post-ARi, $10B+ for 1L mCRPC, $6-$8B for nmCRPC, $10B+ for mHSPC[52] Financial Position - Celcuity has cash, cash equivalents, and short-term investments of $205 million as of Q1 2025, expected to fund operations through 2026[8, 159]

Jaguar Health, Inc. (NASDAQ: JAGX) What's Different????? 3 NASDAQ:JAGX • The classic definition of insanity: Doing the same thing over and over again and expecting a different result • Equally crazy — changing the approach and expecting to get the same results Overview – May 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts conta ...

This document contains forward-looking statements concerning Eton Pharmaceuticals, Inc. ("Eton", the "Company," "we," "us," and "our"). The words "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following ...

Unleashing the Potential of Immuno-Oncology Therapies June 5, 2025 © 2025 Xilio Therapeutics, Inc. 1 Forward-Looking Statements and Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to: development timelines and anticipated milestones for Xilio's programs; the receipt of future contingent payments under Xilio's coll ...

NGN-401 for Rett Syndrome - NGN-401, a gene therapy leveraging EXACT transgene regulation technology, is being developed for Rett syndrome [15] - Rett syndrome affects an estimated 6,000-9,000 patients in the U S [20] - The worldwide incidence of Rett syndrome is estimated at 1 in 10,000 females [20] - Phase 1/2 data showed durable improvements, including a two-point improvement in CGI-I in all participants [38] - All four participants in the Phase 1/2 trial achieved a CGI-I rating of "Much Improved" [41] - The company expects to announce additional Phase 1/2 clinical data in the second half of 2025 [64] Clinical Trial and Regulatory Updates - The FDA has accepted the conversion of the Phase 1/2 trial to a registrational trial for NGN-401 [28] - The Embolden registrational trial is designed as an open-label, single-arm, baseline-controlled study [27] - The proposed number of participants in the Embolden trial is 18, subject to FDA feedback [28] - The company anticipates providing a regulatory update regarding the registrational trial in the first half of 2025 [64] Manufacturing and Financials - Neurogene has a 42,000 sq ft in-house AAV manufacturing facility in Houston, with 6,000 sq ft of cleanrooms [11] - The company's cash runway is expected to fund operations into early 2028 [6, 64]

Company Performance Highlights - Caesars Digital generated over $1.2 billion of TTM Net Revenue and $155 million of Adjusted EBITDA [19] - Caesars Digital's Q1 '25 TTM Net Revenue is 20% above Q1 '24 TTM [19] - Caesars Digital's Q1 '25 TTM Adjusted EBITDA is 230% above Q1 '24 TTM [19] - Las Vegas properties generated over $1.0 billion of TTM Adjusted EBITDAR [30] - Regional properties' capital spend comprises approximately 65% of Q1 2025 Regional segment Adjusted EBITDAR [33] - Caesars Digital's iGaming net gaming revenue increased by 53% YoY in Q1 2025 to $118 million [56, 59] Financial Outlook - The company anticipates $1.35 billion in master lease rent [41] - The company's current weighted average cost of debt is 6.5%, implying $775 million of full-year interest expense [41] - The company projects mid-point capital expenditures of $606 million for 2025, excluding Caesars Virginia JV [41] - The company estimates cash income taxes at approximately 5% of Adjusted EBITDAR [41]